Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03008616 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
A Phase 2 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03008616: Clinical Trial Phase 2 study, sponsored by AMAG Pharmaceuticals.
NCT03008616 is a Phase 2 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03008616, a Phase 2 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
Primary Outcome
Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age
Interventions
- OTHER Placebo
- BIOLOGICAL AMAG-423 (digoxin immune fab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
Why NCT03008616 stopped before completion
NCT03008616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03008616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03008616 about?
NCT03008616 is a clinical study titled "Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia". This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
What is the current status of trial NCT03008616?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-04-12. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03008616?
The interventions under investigation include: Placebo (OTHER), AMAG-423 (digoxin immune fab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03008616?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03008616's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI